This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1999 Aug;106(2):573-4.

doi: 10.1046/j.1365-2141.1999.01622.x.

rHuEpo treatment in low-risk myelodysplastic syndromes

M Laffan, G Vassiliou

PMID: 10460628
DOI: 10.1046/j.1365-2141.1999.01622.x

Case Reports

rHuEpo treatment in low-risk myelodysplastic syndromes

M Laffan et al. Br J Haematol. 1999 Aug.

. 1999 Aug;106(2):573-4.

doi: 10.1046/j.1365-2141.1999.01622.x.

Authors

M Laffan, G Vassiliou

PMID: 10460628
DOI: 10.1046/j.1365-2141.1999.01622.x

No abstract available

PubMed Disclaimer

Comment on

A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes.
Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes; Ferrini PR, Grossi A, Vannucchi AM, Barosi G, Guarnone R, Piva N, Musto P, Balleari E. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, et al. Br J Haematol. 1998 Dec;103(4):1070-4. doi: 10.1046/j.1365-2141.1998.01085.x. Br J Haematol. 1998. PMID: 9886322 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information